Case study · Site-specific FDA 510(k) · NGS
Working with Targeted Genomics, ResearchDx designed the GlutenID assay, wrote every protocol, ran all analytical validation and analyzed the data. The project went from start to FDA submission in 18 months, and the test is now cleared for use in our CLIA-certified laboratory, PacificDx.
At a glance
Client
Targeted Genomics, LLC
Test
GlutenID Celiac Genetic Health Risk Test
FDA outcome
Site-specific 510(k) clearance, K241456 (announced January 28, 2025)
Project start to submission
18 months
Device class
Class II, Genetic Health Risk Assessment System (21 CFR 866.5950)
Use
Over-the-counter, direct-to-consumer, adults 18+
Sample
Saliva, collected at home
Technology
Custom NGS-based SNP panel on the Illumina MiSeqDx, with a full bioinformatics pipeline for haplotype reporting
Testing site
PacificDx, a ResearchDx company: the only laboratory covered by the clearance
The challenge
Targeted Genomics wanted to sell a celiac disease genetic risk test straight to consumers, with no prescription. For an over-the-counter genetic test, FDA requires Class II special controls: full analytical validation, plus proof that lay users understand their results.
The test also went further than the cleared comparison device. The predicate, 23andMe's Personal Genome Service celiac test (DEN160026), reports one risk haplotype, HLA-DQ2.5, using a microarray. GlutenID reports four (HLA-DQ2.5, DQ8, DQ7 and DQ2.2) from six genetic variants, using next-generation sequencing.
The submission was site-specific: FDA reviews the assay as performed in one named laboratory, so that lab's equipment, staff and procedures are part of what gets cleared.
Our approach
Working with Targeted Genomics, ResearchDx designed the assay, wrote every protocol, performed all of the analytical validation studies and did all of the data analysis, then secured the clearance on Targeted Genomics' behalf.
A 510(k) under 21 CFR 866.5950, product code PTA, with 23andMe's celiac genetic health risk test as the predicate.
Saliva collected in an FDA-cleared ORAcollect Dx kit. A custom NGS-based panel sequences six SNPs on the Illumina MiSeqDx, with no-template and positive controls in every run.
A full pipeline calls the variants, assigns HLA-DQ haplotypes and reports one of 15 genotypes with a risk category.
We wrote the study protocols and ran every analytical study: accuracy, precision, DNA extraction, detection limit and interference.
We analyzed all of the validation data, including a user comprehension study showing adults could read their report without a clinician.
Validation ran on the instruments, reagent lots and operators at PacificDx, the CLIA-certified laboratory that now performs the cleared test.
Validation results
Accuracy and precision studies returned 100% correct calls. In the interference studies, the few samples with low DNA or coverage were flagged for rerun rather than miscalled.
Accuracy vs Sanger sequencing
100% agreement
Precision
270/270 correct
DNA extraction and lot-to-lot
198/198 correct
Limit of detection
1 ng/µL
Interference
0 incorrect calls
User comprehension
97.0%
The interference studies set the collection instruction: collect saliva at least 30 minutes after eating, drinking, smoking or brushing teeth.
The outcome
The project went from start to FDA submission in 18 months. FDA cleared GlutenID as a Class II device (K241456), announced on January 28, 2025. Consumers order the test, collect saliva at home and mail it to PacificDx, the one laboratory covered by the clearance, which runs the assay and returns a risk report.
“This outcome is the result of our team's hard work to bring about this important FDA clearance.”
Shelly Gunn, Medical Director, Targeted Genomics
“We are thrilled to have worked with Targeted Genomics to receive FDA 510(k) approval for this innovative diagnostic platform.”
Mathew Moore, Principal, ResearchDx
Sources: FDA 510(k) decision summary, K241456 (PDF) · Press release, January 28, 2025 (PDF)
From assay design and validation to a site-specific clearance in our CLIA/CAP laboratory, talk to our regulatory team about your device's pathway.